MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/560/0.01/20.09.24 | Market Closed - Börse Stuttgart 11:37:53 05/07/2024 pm IST | ||
| 0.062 EUR | +12.73% |
|
| Current month | -7.46% | ||
| 1 month | -34.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 0.062 | +12.73% |
| 04/24/04 | 0.055 | -3.51% |
| 03/24/03 | 0.057 | -3.39% |
| 02/24/02 | 0.059 | -6.35% |
| 01/24/01 | 0.063 | -5.97% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 11:37 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME4N3P |
| ISIN | DE000ME4N3P4 |
| Date issued | 05/12/2023 |
| Strike | 560 $ |
| Maturity | 20/09/2024 (76 Days) |
| Parity | 100 : 1 |
| Emission price | 0.06 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.142 € |
|---|---|
| Lowest since issue | 0.038 € |
| Spread | 0.01 € |
| Spread % | 14.29% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Warrants
- Warrant
